Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancer Trial supported by strong ...

As biopharma innovation becomes increasingly data-driven and autonomous, the integration of Chinese AI- renowned for rapid ...

(NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating ...

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

BACKGROUND: Neurodevelopmental and functional impairments are among the most consequential morbidities for survivors of ...

Dementia associated with Alzheimer’s disease is a progressive neurodegenerative condition characterized by memory loss, cognitive decline, and impaired daily functioning. The growing aging population ...

New leadership to spearhead AI-driven breakthroughs in drug discovery and operational excellence Austin, Texas--(Newsfile ...

Moleculin Biotech, Inc. 40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and ...

Shelton, Connecticut Thursday, July 17, 2025, 18:00 Hrs [IST] ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

This year, the EHA Congress provided us with long-term follow-up of some very interesting study, including the GAIA/CLL13 ...